The problem, as I see it: The method ASMB used to estimate the half-life of cccDNA decay has such a wide confidence interval that it might actually take several years (if it can be done at all) for cccDNA to be eradicated once viral replication has been shut down.
It's good for humanity that somebody is testing to see if a short course of DAA treatment can cure HBV; however, I question whether this is an enterprising pursuit from an investment standpoint.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.